François Lebel

1.8k total citations
45 papers, 846 citations indexed

About

François Lebel is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Epidemiology. According to data from OpenAlex, François Lebel has authored 45 papers receiving a total of 846 indexed citations (citations by other indexed papers that have themselves been cited), including 32 papers in Oncology, 16 papers in Pulmonary and Respiratory Medicine and 9 papers in Epidemiology. Recurrent topics in François Lebel's work include Lung Cancer Treatments and Mutations (12 papers), HER2/EGFR in Cancer Research (11 papers) and CAR-T cell therapy research (10 papers). François Lebel is often cited by papers focused on Lung Cancer Treatments and Mutations (12 papers), HER2/EGFR in Cancer Research (11 papers) and CAR-T cell therapy research (10 papers). François Lebel collaborates with scholars based in United States, Canada and Netherlands. François Lebel's co-authors include Mark A. Socinski, Xiuning Le, Gajanan Bhat, Jeffrey Clarke, Jonathan W. Goldman, George Harb, Robin Cornelissen, Nishan Tchekmedyian, Steeve D. Côté and Christian Dussault and has published in prestigious journals such as Journal of Clinical Oncology, Blood and Cancer Research.

In The Last Decade

François Lebel

45 papers receiving 816 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
François Lebel United States 16 372 324 144 124 115 45 846
Guy Cornu Belgium 15 224 0.6× 176 0.5× 217 1.5× 136 1.1× 157 1.4× 46 977
Ruud G.L. de Sévaux Netherlands 17 131 0.4× 125 0.4× 109 0.8× 233 1.9× 197 1.7× 29 1.0k
T. Benter Germany 17 149 0.4× 173 0.5× 276 1.9× 220 1.8× 98 0.9× 36 951
Ali Kaya Türkiye 15 178 0.5× 144 0.4× 172 1.2× 60 0.5× 83 0.7× 81 700
Peter Bennett Australia 15 126 0.3× 480 1.5× 98 0.7× 166 1.3× 63 0.5× 38 813
Han Vorng France 20 186 0.5× 198 0.6× 186 1.3× 123 1.0× 124 1.1× 46 1.6k
Steven E. Rodgers United States 19 317 0.9× 216 0.7× 251 1.7× 399 3.2× 138 1.2× 39 1.5k
Yutaka Kubota Japan 17 180 0.5× 397 1.2× 142 1.0× 116 0.9× 184 1.6× 79 961
Darrin V. Bann United States 17 185 0.5× 110 0.3× 157 1.1× 94 0.8× 48 0.4× 36 588
Catherine Chung United States 14 217 0.6× 62 0.2× 181 1.3× 57 0.5× 128 1.1× 87 881

Countries citing papers authored by François Lebel

Since Specialization
Citations

This map shows the geographic impact of François Lebel's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by François Lebel with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites François Lebel more than expected).

Fields of papers citing papers by François Lebel

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by François Lebel. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by François Lebel. The network helps show where François Lebel may publish in the future.

Co-authorship network of co-authors of François Lebel

This figure shows the co-authorship network connecting the top 25 collaborators of François Lebel. A scholar is included among the top collaborators of François Lebel based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with François Lebel. François Lebel is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Cornelissen, Robin, Arsela Prelaj, Sophie Sun, et al.. (2023). Poziotinib in Treatment-Naive NSCLC Harboring HER2 Exon 20 Mutations: ZENITH20-4, A Multicenter, Multicohort, Open-Label, Phase 2 Trial (Cohort 4). Journal of Thoracic Oncology. 18(8). 1031–1041. 34 indexed citations
2.
Le, Xiuning, Jacqulyne Robichaux, Monique B. Nilsson, et al.. (2023). 1377P Differential impact of EGFR exon 20 insertion location on tyrosine kinase inhibitor sensitivity. Annals of Oncology. 34. S790–S790. 2 indexed citations
3.
Cornelissen, Robin, Sanyuan Sun, Marina Chiara Garassino, et al.. (2021). LBA46 Efficacy and safety of poziotinib in treatment-naïve NSCLC harboring HER2 exon 20 mutations: A multinational phase II study (ZENITH20-4). Annals of Oncology. 32. S1324–S1324. 6 indexed citations
4.
Sacher, Adrian G., Xiuning Le, Robin Cornelissen, et al.. (2021). 36MO Safety, tolerability and preliminary efficacy of poziotinib with twice daily strategy in EGFR/HER2 Exon 20 mutant non-small cell lung cancer. Annals of Oncology. 32. S15–S15. 19 indexed citations
5.
Le, Xiuning, Robin Cornelissen, Marina Chiara Garassino, et al.. (2021). Poziotinib in Non–Small-Cell Lung Cancer Harboring HER2 Exon 20 Insertion Mutations After Prior Therapies: ZENITH20-2 Trial. Journal of Clinical Oncology. 40(7). 710–718. 99 indexed citations
6.
Tchekmedyian, Nishan, et al.. (2020). Prolonged Central Nervous System Response in a Patient With HER2 Mutant NSCLC Treated With First-Line Poziotinib. JTO Clinical and Research Reports. 1(4). 100081–100081. 1 indexed citations
7.
Socinski, Mark A., Robin Cornelissen, Marina Chiara Garassino, et al.. (2020). LBA60 ZENITH20, a multinational, multi-cohort phase II study of poziotinib in NSCLC patients with EGFR or HER2 exon 20 insertion mutations. Annals of Oncology. 31. S1188–S1188. 31 indexed citations
8.
Barrett, John, Hongliang Cai, Pranay D. Khare, et al.. (2018). Regulated intratumoral expression of IL-12 using a RheoSwitch Therapeutic System® (RTS®) gene switch as gene therapy for the treatment of glioma. Cancer Gene Therapy. 25(5-6). 106–116. 76 indexed citations
9.
10.
Nemunaitis, John, Gerald P. Linette, Omid Hamid, et al.. (2014). Regulated intratumoral expression of IL-12 as a basis for combination therapy in melanoma. Journal of Translational Medicine. 12(S1). 15 indexed citations
11.
Mace, Sharon E., George Harb, Keith Friend, et al.. (2013). Cost-effectiveness of recombinant human hyaluronidase-facilitated subcutaneous versus intravenous rehydration in children with mild to moderate dehydration. The American Journal of Emergency Medicine. 31(6). 928–934. 11 indexed citations
12.
Spandorfer, Philip R., Sharon E. Mace, Pamela J. Okada, et al.. (2012). A Randomized Clinical Trial of Recombinant Human Hyaluronidase-Facilitated Subcutaneous Versus Intravenous Rehydration in Mild to Moderately Dehydrated Children in the Emergency Department. Clinical Therapeutics. 34(11). 2232–2245. 28 indexed citations
13.
Harb, George, et al.. (2011). Techniques for Hyaluronidase-Facilitated Subcutaneous Fluid Administration With Recombinant Human Hyaluronidase. Journal of Infusion Nursing. 34(5). 300–307. 5 indexed citations
14.
15.
16.
Lebel, François, et al.. (1992). Human Herpesvirus 6 and Chronic Fatigue Syndrome. Canadian Journal of Infectious Diseases and Medical Microbiology. 4(4). 199–202. 8 indexed citations
17.
Lebel, François, et al.. (1992). Cryptococcal cerebrospinal fluid shunt infection treated with fluconazole. Canadian Journal of Infectious Diseases and Medical Microbiology. 4(4). 227–228. 1 indexed citations
18.
Shennib, Hani, Moisés Mercado, Dao Nguyen, et al.. (1991). Successful Treatment of Steroid-resistant Double-Lung Allograft Rejection with Orthoclone® OKT3. American Review of Respiratory Disease. 144(1). 224–226. 15 indexed citations
19.
Bourgault, Anne–Marie, et al.. (1990). Ghost mycobacteria on Gram stain. Journal of Clinical Microbiology. 28(1). 146–147. 17 indexed citations
20.
Thibert, Louise, François Lebel, B Martineau, & L Chicoine. (1988). Mycobacterium haemophilum in Quebec.. PubMed. 14(42). 196–196. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Guy Cornu Breakdown of academic impact, for papers by Ruud G.L. de Sévaux Breakdown of academic impact, for papers by T. Benter Breakdown of academic impact, for papers by Ali Kaya Breakdown of academic impact, for papers by Peter Bennett Breakdown of academic impact, for papers by Han Vorng Breakdown of academic impact, for papers by Steven E. Rodgers Breakdown of academic impact, for papers by Yutaka Kubota Breakdown of academic impact, for papers by Darrin V. Bann Breakdown of academic impact, for papers by Catherine Chung
Rankless by CCL
2026